Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can routine scans predict how pancreatic tumors behave?

NCT ID NCT05714111

Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers at IRCCS San Raffaele are building a registry of radiology and clinical data from adults with suspected or diagnosed pancreatic cancer, pancreatic cysts, or other pancreatic disease. The registry gathers retrospective scans from 2014 onward and prospective scans through 2027, with up to three years of follow-up per patient. By matching imaging findings with outcomes such as progression-free survival and overall survival, the study aims to learn which radiological features help assess malignancy and prognosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry links imaging patterns to outcomes, doctors could better predict which pancreatic tumors will grow and choose treatments more precisely.
What could go wrong
This is an observational registry, not a treatment trial, so it cannot prove that any scan or procedure changes outcomes. The data may be incomplete or inconsistent across years, and findings may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, rare forms of pancreatic cancer (such as ampullary cancer, adenosquamous carcinomas, squamous cell carcinomas, signet ring cell carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with giant cells) and cystic neoplasms.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age * Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage. * able and willing to sign informed consent Exclusion Criteria: * Patients with non-primary pancreatic disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas cyst are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreas disorder Pancreatic Cyst pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreas cyst Pancreas disease Pancreas neoplasm Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Radiology, IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, 20132, Italy

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.